Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
| ▸ | GPR3 | P46089 | 1/20 | 0.30 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18859627 | 0.88 | ELANE (0.36) | ELANEADORA2AKDM4EGAAMAPT | |
| SCHEMBL18803208 | 0.84 | ELANE (0.40) | ELANEADORA2AKDM4EGAAMAPT | |
| SCHEMBL18370825 | 0.84 | ADORA2A (0.34) | ELANEADORA2AADORA1 | |
| SCHEMBL18859608 | 0.83 | ELANE (0.34) | ELANEADORA2AADORA1KDM4EGAA | |
| SCHEMBL18370827 | 0.83 | ADORA2A (0.35) | ELANEADORA2AADORA1KDM4E | |
| SCHEMBL18803452 | 0.81 | IDO1 (0.39) | ELANEMAPT | |
| SCHEMBL18859604 | 0.80 | ELANE (0.34) | ELANEADORA2AMAPTADKGPR3 | |
| SCHEMBL18859681 | 0.79 | GPR3 (0.37) | ELANEMAPTADKGPR3 | |
| SCHEMBL18859611 | 0.79 | F9 (0.37) | ELANEKDM4EMAPTADK | |
| SCHEMBL18859576 | 0.79 | TNKS (0.36) | ADORA2AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10644244-B2 | Heterocyclic compound and organic light emitting device using same | LT MATERIALS CO., LTD. (KR) | 2020-05-05 | — | — | US | disclosed |
| US-20170141325-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | HEESUNG MATERIAL LTD. (KR) | 2017-05-18 | — | — | US | disclosed |
| US-20170141325-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | HEESUNG MATERIAL LTD. (KR) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170141325-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | CRY1, CRY2, CYBA | ELANE 4401/4885ADORA2A 2164/4885ADORA1 3731/4885 |
| US-10644244-B2 | Heterocyclic compound and organic light emitting device using same | CRY1, CRY2, CYBA | ELANE 4401/4885ADORA2A 2164/4885ADORA1 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.